SVB Leerink Boosts Lantheus (NASDAQ:LNTH) Price Target to $127.00

Lantheus (NASDAQ:LNTH) had its price target lifted by SVB Leerink from $106.00 to $127.00 in a research note released on Thursday, Benzinga reports. They currently have an outperform rating on the medical equipment provider’s stock.

LNTH has been the subject of several other reports. StockNews.com lowered shares of Lantheus from a buy rating to a hold rating in a research note on Friday, May 3rd. Mizuho upped their price target on shares of Lantheus from $90.00 to $100.00 and gave the company a buy rating in a report on Friday, May 3rd. B. Riley raised their price objective on shares of Lantheus from $95.00 to $99.00 and gave the stock a buy rating in a research note on Thursday, April 18th. JMP Securities upped their target price on Lantheus from $100.00 to $130.00 and gave the company an outperform rating in a research note on Wednesday. Finally, Truist Financial increased their price target on Lantheus from $82.00 to $96.00 and gave the stock a buy rating in a report on Friday, May 3rd. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $113.86.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $123.42 on Thursday. The firm has a fifty day simple moving average of $81.97 and a two-hundred day simple moving average of $67.84. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $8.55 billion, a P/E ratio of 18.84 and a beta of 0.51. Lantheus has a 52 week low of $50.20 and a 52 week high of $124.90.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, topping the consensus estimate of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The company had revenue of $369.98 million during the quarter, compared to analyst estimates of $349.46 million. On average, analysts expect that Lantheus will post 6.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the sale, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $76.89, for a total transaction of $26,219.49. Following the transaction, the chief accounting officer now directly owns 62,898 shares in the company, valued at approximately $4,836,227.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Heinz Christoph Maeusli sold 18,373 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the completion of the sale, the director now owns 23,340 shares of the company’s stock, valued at approximately $1,848,294.60. The disclosure for this sale can be found here. Insiders have sold a total of 44,799 shares of company stock valued at $3,748,151 over the last quarter. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. UMB Bank n.a. boosted its position in Lantheus by 161.4% during the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares in the last quarter. Principal Securities Inc. purchased a new position in shares of Lantheus in the 4th quarter worth approximately $28,000. Fidelis Capital Partners LLC purchased a new position in shares of Lantheus in the 1st quarter worth approximately $34,000. Finally, FinTrust Capital Advisors LLC raised its stake in shares of Lantheus by 53.6% during the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after acquiring an additional 232 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.